Search

Your search keyword '"Cheung, S. Y. A."' showing total 48 results

Search Constraints

Start Over You searched for: Author "Cheung, S. Y. A." Remove constraint Author: "Cheung, S. Y. A." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
48 results on '"Cheung, S. Y. A."'

Search Results

1. Search for gravitational waves emitted from SN 2023ixf

2. A search using GEO600 for gravitational waves coincident with fast radio bursts from SGR 1935+2154

3. Observation of Gravitational Waves from the Coalescence of a $2.5\text{-}4.5~M_\odot$ Compact Object and a Neutron Star

5. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

6. Pediatric oncology drug development and dosage optimization.

9. How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement

10. Use of pharmacodynamic modeling for Bayesian information borrowing in pediatric clinical trials.

13. Cost effectiveness analyses of pharmacological treatments in heart failure

15. Supporting Prospective Pregnancy Trials via Modeling and Simulation: Lessons From the Past and Recommendations for the Future.

17. Epstein-Barr Virus Reactivation After Paediatric Haematopoietic Stem Cell Transplantation: Risk Factors and Sensitivity Analysis of Mathematical Model

19. 1013. Predicting RSV Efficacy for MK-1654 in Temperate and Tropical Climates using MBMA and Clinical Trial Simulation to Account for Seasonal Differences in RSV Force-of-Infection

21. 998. Forward and Reverse Translational Approaches to Predict Efficacy of the Neutralizing Respiratory Syncytial Virus (RSV) Antibody MK-1654

24. Reproductive Realities in Modern China: Birth Control and Abortion, 1911–2021.

25. Artificial Intelligence and Machine Learning Applied at the Point of Care

26. Pediatric Extrapolation in Type 2 Diabetes: Future Implications of a Workshop

27. Concentration‐QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.

28. Danya Glabau, Food Allergy Advocacy: Parenting and the Politics of Care.

29. V2ACHER: Visualization of complex trial data in pharmacometric analyses with covariates.

30. A phase i open-label study to identify a dosing regimen of the pan-akt inhibitor azd5363 for evaluation in solid tumors and in pik3ca-mutated breast and gynecologic cancers

32. Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

33. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

34. Advanced methods for dose and regimen finding during drug development:Summary of the EMA /EFPIA workshop on dose finding (London 4-5 December 2014)

35. How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.

37. Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)

38. Abstract CT135: A pre-surgical window of opportunity study to investigate the biomarker effects of DNA damage response (DDR) agents in patients (pts) with head and neck squamous cell carcinoma (HNSCC)

40. Advanced Methods for Dose and Regimen Finding During Drug Development : Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014)

41. Dose-exposure-response relationship between AZD6738 and peripheral monocytes.

42. Understanding Hematological Toxicities Using Mathematical Modeling.

43. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.

46. Correction to: How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.

47. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

48. Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Catalog

Books, media, physical & digital resources